NCT07009457View on ClinicalTrials.gov

Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 16, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2028

Conditions
Widespread Small Cell Lung Cancer
Interventions
DRUG

SHR-1316 (sc) Injection

SHR-1316 (sc) injection.

DRUG

SHR-1316 Injection

SHR-1316 injection.

DRUG

Carboplatin Injection

Carboplatin injection.

DRUG

Etoposide Injection

Etoposide injection.

Trial Locations (1)

330200

RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT07009457 - Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter